Aref Al‐Kali

7.0k citations

210 papers · 2.5k indexed · h-index 25

Impact in

Hematology top 0.5%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Genetics top 0.5%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research

Papers in

Hematology 182
- Acute Myeloid Leukemia Research 156
- Chronic Myeloid Leukemia Treatments 68
Genetics 109
- Myeloproliferative Neoplasms: Diagnosis and Treatment 78
- Chronic Lymphocytic Leukemia Research 29

Co-authors: Mark R. Litzow Ayalew Tefferi Animesh Pardanani Kebede H. Begna Naseema Gangat Mrinal M. Patnaik William J. Hogan Terra L. Lasho
Journals: Blood (76 papers)American Journal of Hematology (16 papers)Journal of Clinical Oncology (13 papers)Blood Cancer Journal (12 papers)British Journal of Haematology (8 papers)
Partner nations: United States Germany Italy

In The Last Decade

Aref Al‐Kali

190 papers receiving 2.4k citations

Peers

Countries citing papers authored by Aref Al‐Kali

Since Specialization

Citations

This map shows the geographic impact of Aref Al‐Kali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aref Al‐Kali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aref Al‐Kali more than expected).

Fields of papers citing papers by Aref Al‐Kali

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aref Al‐Kali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aref Al‐Kali. The network helps show where Aref Al‐Kali may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Aref Al‐Kali, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Aref Al‐Kali Line = papers co-authored together Aref Al‐Kali links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations Blood ·Talha Badar, 王奎龙, Sabina Bodył-Gajowska, Terra L. Lasho, Yael Kusne, Christy M. Finke, James M. Foran, Mohamed A. Kharfan‐Dabaja, Hemant S. Murthy, Yao‐Shan Fan, Liuyan Jiang, Naseema Gangat, Abhishek A. Mangaonkar, Aref Al‐Kali, Ludovica Marando, Ayalew Tefferi, Peng Xiao-qin, David S. Viswanatha, Mark R. Litzow, Mrinal M. Patnaik	2024	1
2	Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53-mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series Blood ·Talha Badar, Sabina Bodył-Gajowska, 王奎龙, James M. Foran, Mohamed A. Kharfan‐Dabaja, Hemant S. Murthy, Naseema Gangat, Aref Al‐Kali, Mithun Vinod Shah, Hassan B. Alkhateeb, Antoine N. Saliba, William J. Hogan, Eyouel Shimeles, Lisa Sproat, Jeanne Palmer, Mark R. Litzow, Mrinal M. Patnaik	2024	1
3	TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance Blood ·Ayalew Tefferi, Ana Carolina Moraes Aboin, Giuseppe Gaetano Loscocco, F. Vaienti, Aref Al‐Kali, James M. Foran, Jeanne Palmer, Talha Badar, Mrinal M. Patnaik, Kaaren K. Reichard, Peng Xiao-qin, F Magaña-Sandoval, Mithun Vinod Shah, Attilio Orazi, Daniel A. Arber, Animesh Pardanani, Alessandro M. Vannucchi, Devendra Hiwase, Naseema Gangat, Paola Guglielmelli	2024	0
4	T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia Blood Advances ·Talha Badar, Keith L. Knutson, James M. Foran, Naseema Gangat, Kevin D. Pavelko, Scott H. Kaufmann, Mark R. Litzow, Hemant S. Murthy, 卢晓东, Tung Ba Le, 三菱重工業株式会社下関造船所, Aref Al‐Kali, Hassan B. Alkhateeb, Ayalew Tefferi, Mrinal M. Patnaik, Mithun Vinod Shah	2024	6
5	PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis American Journal of Hematology ·Ayalew Tefferi, Fiorella Olivera Rojas, Thiago Djoseff Pinheiro Reis, R Din Parast, Sernard Drimmer, Ana Carolina Moraes Aboin, Clifford M. Csizmar, Mark E. Gurney, Terra L. Lasho, Christy M. Finke, Abhishek A. Mangaonkar, Aref Al‐Kali, Animesh Pardanani, Kaaren K. Reichard, Rong He, Naseema Gangat, Mrinal M. Patnaik	2024	2
6	Clinical and molecular correlates of somatic and germline <i>DDX41</i> variants in patients and families with myeloid neoplasms Haematologica ·Talha Badar, Ryuusuke Harada, James M. Foran, David S. Viswanatha, Aref Al‐Kali, Terra L. Lasho, Christy M. Finke, Hassan B. Alkhateeb, Rong He, Naseema Gangat, Mithun Vinod Shah, Ayalew Tefferi, Abhishek A. Mangaonkar, Mark R. Litzow, Oonishi Mami, Timothy M. Chlon, Alejandro Ferrer, Mrinal M. Patnaik	2023	10
7	Venetoclax + Cladribine + Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax + Hypomethylating Agent Blood ·Svenja Sers, Kristen McCullough, Aref Al‐Kali, Hassan B. Alkhateeb, Kebede H. Begna, Abhishek A. Mangaonkar, Antoine N. Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun Vinod Shah, Animesh Pardanani, Talha Badar, Hemant S. Murthy, James M. Foran, Eyouel Shimeles, Ayalew Tefferi, Naseema Gangat	2023	1
8	U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity Blood Cancer Journal ·Talha Badar, Thiago Goçalves Pereira, Ryuusuke Harada, James M. Foran, Aref Al‐Kali, Abhishek A. Mangaonkar, Hemant S. Murthy, Hassan B. Alkhateeb, David S. Viswanatha, Rong He, Mithun Vinod Shah, Juan Chow, Mark R. Litzow, Naseema Gangat, Ayalew Tefferi, Mrinal M. Patnaik	2023	7
9	A phase II study of combination daunorubicin, cytarabine (Ara‐c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression American Journal of Hematology ·Aref Al‐Kali, Raoul Tibes, Pamela J. Atherton, Jeanne Palmer, Hassan B. Alkhateeb, Mrinal M. Patnaik, Kebede H. Begna, Naseema Gangat, Shahrukh K. Hashmi, Rong He, Mark R. Litzow	2023	5
10	Allogeneic Stem Cell Transplant Outcomes in Patients with DDX41 Mutated Myeloid Malignancies Transplantation and Cellular Therapy ·Anmol Baranwal, Aref Al‐Kali, James M. Foran, David S. Viswanatha, Rong He, Mrinal M. Patnaik, Abhishek A. Mangaonkar, Mithun Vinod Shah, Mark R. Litzow, William J. Hogan, Hassan B. Alkhateeb	2022	1
11	Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms American Journal of Hematology ·Mithun Vinod Shah, Rakchha Chhetri, T Martin, Chung Hoow Kok, Naseema Gangat, Hassan B. Alkhateeb, Aref Al‐Kali, Mrinal M. Patnaik, Anmol Baranwal, Patricia T. Greipp, Rong He, Kebede H. Begna, Ing Soo Tiong, Andrew H. Wei, Devendra Hiwase	2022	8
12	European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response Blood Cancer Journal ·Kebede H. Begna, Vasco Maria Lopes Madureira Falcão Galvão, Naseema Gangat, Hassan B. Alkhateeb, Mrinal M. Patnaik, Aref Al‐Kali, M. A. Elliott, William J. Hogan, Mark R. Litzow, Animesh Pardanani, Curtis A. Hanson, Rhett P. Ketterling, Ayalew Tefferi	2022	4
13	A dynamic 3‐factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy American Journal of Hematology ·Ayalew Tefferi, Naseema Gangat, Aref Al‐Kali, Hassan B. Alkhateeb, Mithun Vinod Shah, Mrinal M. Patnaik, Michelle A. Elliott, William J. Hogan, Mark R. Litzow, C. Christopher Hook, Abhishek A. Mangaonkar, David S. Viswanatha, Dong Chen, Animesh Pardanani, Rhett P. Ketterling, Courtney D. DiNardo, Tapan M. Kadia, Farhad Ravandi, Koji Sasaki, Kebede H. Begna	2022	6
14	Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapy American Journal of Hematology ·Kebede H. Begna, Naseema Gangat, Aref Al‐Kali, Mark R. Litzow, William J. Hogan, Mrinal M. Patnaik, Animesh Pardanani, C. Christopher Hook, Alexandra P. Wolanskyj, Michelle A. Elliott, Curtis A. Hanson, Rhett P. Ketterling, Ayalew Tefferi	2021	4
15	Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis Leukemia & lymphoma ·Rami S. Komrokji, A. K. Takahata, Najla Al Ali, Onyee Chan, Virginia M. Klimek, Brian Ball, Mikkael A. Sekeres, G. W. Lucas, Jaroslaw P. Maciejewski, David A. Sallman, Eric Padron, Andrew Kuykendall, Terra L. Lasho, Aref Al‐Kali, Kiran Naqvi, David P. Steensma, Guillermo Garcia‐Manero, Mrinal M. Patnaik	2021	2
16	Genetic features and clinical outcomes of patients with isolated and comutatedDDX41-mutated myeloid neoplasms Blood Advances ·Hassan B. Alkhateeb, Ryuusuke Harada, David S. Viswanatha, James M. Foran, Talha Badar, Lisa Sproat, Rong He, Phuong L. Nguyen, Dragan Jevremović, H.T. Brodrick, Patricia T. Greipp, Naseema Gangat, Ayalew Tefferi, Mark R. Litzow, Abhishek A. Mangaonkar, Mithun Vinod Shah, Mrinal M. Patnaik, Aref Al‐Kali	2021	27
17	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients American Journal of Hematology ·Erika Morsia, Kristen McCullough, J. Gutiérrez del Olmo, Joselle Cook, Hassan B. Alkhateeb, Aref Al‐Kali, Kebede H. Begna, Michelle A. Elliott, William J. Hogan, Mark R. Litzow, Mithun Vinod Shah, Animesh Pardanani, Mrinal M. Patnaik, Ayalew Tefferi, Naseema Gangat	2020	89
18	Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience Leukemia & lymphoma ·Firas Baidoun, Dong Chen, Mrinal M. Patnaik, Naseema Gangat, Kebede H. Begna, Michelle A. Elliott, William J. Hogan, Mark R. Litzow, Aref Al‐Kali	2019	2
19	Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA Methylation in Acute Myeloid Leukemia Clinical Cancer Research ·Na Shen, Fei Yan, Jiuxia Pang, Na Zhao, Naseema Gangat, Lai‐Chu Wu, Ann M. Bode, Aref Al‐Kali, Mark R. Litzow, Shujun Liu	2017	31
20	Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy Leukemia & lymphoma ·Jason N. Barreto, Kristen McCullough, Metha Ariana Milanda, Ross Dierkhising, Kristin C. Mara, Michelle A. Elliott, Dennis A. Gastineau, Aref Al‐Kali, Naseema Gangat, Louis Letendre, William J. Hogan, Mark R. Litzow, Mrinal M. Patnaik	2017	11

About Aref Al‐Kali

Aref Al‐Kali is a scholar working on Hematology, Genetics, Emergency Medicine, Public Health, Environmental and Occupational Health and Cancer Research, having authored 210 papers that have together received 2.5k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (156 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (78 papers), Chronic Myeloid Leukemia Treatments (68 papers), Acute Lymphoblastic Leukemia research (30 papers), Chronic Lymphocytic Leukemia Research (29 papers), Hematological disorders and diagnostics (13 papers), Eosinophilic Disorders and Syndromes (13 papers) and Histone Deacetylase Inhibitors Research (11 papers). The work is most often cited by research in Hematology (1.6k citations), Genetics (1.1k citations), Molecular Biology (1.1k citations), Rheumatology (240 citations) and Cancer Research (204 citations). Aref Al‐Kali has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Mark R. Litzow, Ayalew Tefferi, Animesh Pardanani, Kebede H. Begna, Naseema Gangat, Mrinal M. Patnaik, William J. Hogan, Terra L. Lasho, Christy M. Finke and Curtis A. Hanson. Their work appears in journals such as Blood, American Journal of Hematology, Journal of Clinical Oncology, Blood Cancer Journal and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact